Investing.com -- French pharmaceutical company Sanofi (EPA: SASY) has agreed to purchase U.K.-based vaccine developer Vicebio in a deal worth up to $1.6 billion, the company announced Tuesday.

Sanofi to acquire Vicebio, expanding respiratory vaccines pipeline. Paris, July 22, 2025. Sanofi today announces it has entered into an agreement to acquire Vicebio Ltd, a privately held ...

LONDON, July 22, 2025 /PRNewswire/ -- Vicebio Ltd ("Vicebio" or the "Company"), a biopharmaceutical company developing novel vaccines against life-threatening respiratory viral infections, has ...

France's Sanofi to acquire biotech firm Vicebio for $1.15 billion French pharmaceuticals company Sanofi said on Tuesday it would acquire British private biotechnology firm Vicebio for a total of ...

Sanofi plans on continuing Vicebio’s scheduled pipeline of vaccines, including Vxb-241, which is currently in Phase 1 study for older adults. Vxb-251, a preclinical trivalent vaccine candidate targets ...

The transaction is expected to close by the end of 2025, and will not have a significant impact on Sanofi’s financial guidance for 2025. The pharma giant’s share price was down around 0.4% ...

LONDON — Sanofi on Tuesday said it would buy the vaccine-focused biotech Vicebio for more than $1 billion upfront, picking up an experimental shot targeting RSV and a vaccine approach that ...

Sanofi to acquire Vicebio, expanding respiratory vaccines pipeline Paris, July 22, 2025. Sanofi today announces it has entered into an agreement to acquire Vicebio Ltd (“Vicebio”), a privately ...

Vicebio Ltd ("Vicebio" or the "Company"), a biopharmaceutical company developing novel vaccines against life-threatening respiratory viral infections, has entered an exclusive, definitive agreement to ...